GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Influenza [types A and B] (quadrivalent) vaccine overview

Flucelvax quadrivalent (Flucelvax Tetra, Flucelvax Quad, Fluad Quad) is a cell based influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line, acts as an immunizing agent. It is formulated as suspension for intramuscular route of administration. Flucelvax quadrivalent contains : A/Brisbane/10/2010 (H1N1) (an A/California/7/2009- like virus); A/Hong Kong/4801/2014 (H3N2); B/Utah/9/14 (a B/Phuket/3073/2013-like virus); B/Hong Kong/259/2010 (a B/Brisbane/60/08- like virus). Flucelvax quadrivalent is indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Flucelvax quadrivalent is also indicated for the active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B for people aged two years and older. Flucelvax Quadrivalent is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine for use in children 6 months of age and older.

Flucelvax tetra is also under development for the prevention of influenza A virus subtypes including H1N1 and H3N2 infections and influenza B virus infections in adults and children from 2 years of age. It is under development for the treatment of 6 months through 47 months pediatrics for unspecified influenza virus infections.

CSL overview

CSL is a biotechnology company. It discovers, develops, manufactures, commercializes and distributes biopharmaceuticals. The company’s product portfolio comprises treatments for hemophilia and immune deficiency, vaccines to prevent influenza and therapies for iron deficiency and kidney conditions. CSL‘s proprietary platform consists of plasma and recombinant protein technology, cell and gene therapy and adjuvant cell-based egg-based mRNA. CSL focuses on conditions related to hematology, respiratory, cardiovascular and metabolic, nephrology and transplant, immunology and vaccines, among others. The company operates in various countries including Australia, China, Germany, Switzerland, the US, Hungary, Puerto Rico, the UK, Italy, Japan, the Netherlands and Spain. CSL is headquartered in Melbourne, Victoria, Australia.

For a complete picture of Influenza [types A and B] (quadrivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.